[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-disorders":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100597547","prevalence-of-thyroid-disorders-in-patients-with-immune-thrombocytopenic-purpura-and-its-impact-on-treatment-100597547",false,"NCT07059910","Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment","Inclusion Criteria:\n\n* ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.\n\n  * refractory ITP patients.\n\nExclusion Criteria:\n\n* patients with history of thyroidectomy\n\n  * patients with history of drug induced ITP\n  * patients with history of HCV, HBV and HIV infection.\n  * Patients who refuse to contribute in this study.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment",[23,24],"Immune Thrombocytopenic Purpura","Thyroid Disorders","NOT_YET_RECRUITING","2025-07-13",{"date":28,"type":29},"2025-07-17","ACTUAL",{"date":31,"type":19},"2025-07",{"date":33,"type":19},"2026-08-15",{"name":35,"class":36},"Assiut University","OTHER"]